Pharvaris’ deucrictibant shows safety and tolerability in Phase 2 HAE study

Pharvaris is highlighting the differentiated profile of deucrictibant as a prophylactic and on-demand treatment of hereditary angioedema – HAE – attacks at the Bradykinin Symposium 2024 in Berlin September 5-6. “Based on a snapshot analysis, treatment with deucrictibant led to a 93% reduction in attack rate compared to study baseline, a median attack rate of zero for every month, and a mean proportion of attack-free days of 99% after more than a year of mean duration of treatment in a prophylactic extension study. Together with the improvements in disease control and health-related quality of life observed in the randomized, placebo-controlled part of the CHAPTER-1 study, these data underscore the potential of deucrictibant to be an effective and well-tolerated prophylactic agent in the treatment of HAE,” said CMO Peng Lu. CHAPTER-1 is a two-part Phase 2 study evaluating the efficacy and safety of deucrictibant for long-term prophylaxis of HAE attacks. Positive top-line data from the double-blind, randomized, placebo-controlled portion of the CHAPTER-1 study were announced in December 2023. Further exploration of disease control, health-related quality of life, and treatment satisfaction data show that 90% of participants receiving deucrictibant reported well-controlled HAE at week 12 compared to 37.5% of participants receiving placebo as measured by the Angioedema Control Test. Deucrictibant-treated participants reported greater satisfaction than those treated with placebo with regards to effectiveness and the domain of global satisfaction, and a comparable satisfaction for side effects. Deucrictibant reduced the attack rate in the open-label extension by 93.0% compared to the part 1 study baseline. The occurrence of “moderate and severe” attacks and of attacks treated with on-demand medication remained low in the open-label extension.